Clinical Trials Logo

Chronic Cough clinical trials

View clinical trials related to Chronic Cough.

Filter by:

NCT ID: NCT04866563 Recruiting - Chronic Cough Clinical Trials

A Study of Efficacy and Safety of AX-8 in Chronic Cough

Start date: July 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, crossover, multicenter study of AX-8 in participants with unexplained or refractory chronic cough designed to evaluate the effectiveness of AX-8 in reducing cough frequency.

NCT ID: NCT04861155 Recruiting - Chronic Cough Clinical Trials

Validation and Evaluation of a Novel Cough Detection Device

Start date: April 22, 2021
Phase: N/A
Study type: Interventional

When diagnosing chronic cough (cough lasting longer than 8 weeks), the physician nowadays very often relies on the patient's narrative and description. In our research project we want to find out whether a cough detector can continuously and reliably record the cough, how the user-friendliness of the cough detector is assessed and whether this continuous recording can support the physician in his diagnosis.

NCT ID: NCT04765722 Not yet recruiting - Asthma Clinical Trials

Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases

MUCOSA
Start date: August 2021
Phase: Phase 4
Study type: Interventional

Cough is the most common presenting symptom to family physician. Chronic Cough affects approximately 10-12% of the general population and is one of the commonest reasons for referral to secondary care. Unfortunately, there are no licensed treatments for this debilitating condition, which is associated with a poor quality of life, affecting the social, physical and psychological well-being of patients. The aim of this single-centre proof-of-concept study is to investigate whether mepolizumab reduces objective cough frequency in patients with eosinophilic asthma and non-asthmatic eosinophilic bronchitis presenting with chronic cough. Secondary outcomes including the effects on quality of life, the intensity of irritant sensations, airway hyper-reactivity and inflammatory cells and their progenitors will also be evaluated. The investigators hypothesize that in patients with asthma and non-asthmatic eosinophilic bronchitis, eosinophils are involved in sensitizing airway nerves and thereby increasing spontaneous objective coughs. The investigators predict that treatment with mepolizumab will reduce airway eosinophilia in patients with chronic cough due to eosinophilic asthma and non-asthmatic eosinophilic bronchitis, thereby causing a reduction in objective cough frequency.

NCT ID: NCT04758351 Not yet recruiting - Chronic Cough Clinical Trials

Prospective Study on the Evaluation, Patient Reported Outcomes and Effectiveness of Treatment for Chronic Cough

PROCOUGH
Start date: August 2021
Phase:
Study type: Observational

Chronic cough is a common troublesome symptom which has a global prevalence of approximately 10%, but with wide variations across continents. The aim of this study is to evaluate the effectiveness of treatment, patient-reported outcomes and burden of disease in patients with chronic cough referred to a specialist clinic. The proposed study will use pre-defined diagnostic criteria, investigations and treatment algorithms such that all recruited patients will undergo the same investigations and follow a set management algorithm. This study will objectively and subjectively assess coughing at baseline and after treatment in a real-world clinical setting. This will allow us to understand the relationship between any objective reduction in cough after treatment, and whether this translates to any significant improvement in subjective questionnaire scores. We will assess the impact of health conditions on lost productivity in monetary units and assess the amount of absenteeism, presenteeism and daily activity impairment attributable to unexplained chronic cough/refractory chronic cough. Finally, a patient survey at the end of the study will evaluate the patients' satisfaction and experience of investigation, management trials and use of questionnaires.

NCT ID: NCT04694963 Not yet recruiting - Pertussis Clinical Trials

A Multi-center Study to Determine the Prevalence and Influence of Pertussis on Subacute Cough in Shenzhen

Start date: January 1, 2021
Phase:
Study type: Observational

A prospective, multi-center, observational clinical trail. Aim to evaluate the real incidence of COPD pertussis and the impact of pertussis on subaute cough.

NCT ID: NCT04654481 Recruiting - Covid19 Clinical Trials

Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic

Start date: December 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the addition of high frequency chest wall oscillation (HFCWO) therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-COVID patients with COPD and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from COVID-19.

NCT ID: NCT04525885 Recruiting - Chronic Cough Clinical Trials

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

Start date: May 17, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

NCT ID: NCT04110054 Completed - Chronic Cough Clinical Trials

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Start date: February 13, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.

NCT ID: NCT03864328 Terminated - Chronic Cough Clinical Trials

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF

SCENIC
Start date: March 29, 2019
Phase: Phase 2
Study type: Interventional

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough. Cough in IPF is both a presenting and a complicating clinical feature, which affects approximately three quarters of IPF cases. It is often a debilitating symptom that adversely affects quality of life (QoL) and is usually refractory to medical therapy. Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b study for the treatment of persistent cough in patients with IPF.

NCT ID: NCT03787511 Recruiting - Type 2 Diabetes Clinical Trials

Chronic Cough and Small Fiber Neuropathy

CHROCOS
Start date: March 5, 2019
Phase: N/A
Study type: Interventional

Diabetic patients with and without chronic cough will be included in this study. After giving their informed consent, the patients will perform a spirometry, chest X-ray at the inclusion visit. Cough will be assessed using the cough visual analog scale (VAS) and the Leicester Cough Questionnaire (LCQ). Within 60 days, the patient will perform neurophysiological tests. The neurophysiological assessment will be concluded with a skin biopsy to evaluate small fiber neuropathy. The aim of the study is to compare the proportion of small fiber neuropathy between diabetic patients with chronic cough and those without chronic cough.